Allergy Thera. Share News (AGY)

Allergy Therapeutics gets green light for hay fever study in Canada

Speciality pharmaceuticals firm Allergy Therapeutics has received the approval from the Canadian health regulators to submit a full clinical trial application for a new study of its hay fever vaccine. Following on from successful discussions held with the US Food and Drug Administration previously,

Allergy Therapeutics' Hay Fever CTA Approved By Health Canada

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday that the Canadian health authority has approved its proposal to submit a full clinical trial application for an efficacy study for Pollinex Quattro Grass MATA MPL (0.5ml). The speciality pharma firm said its proposal for a new

Allergy Therapeutics Says Positive Ragweed Allergy Treatment Published

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that results from its Phase IIb clinical trial of its Pollinex Quattro ragweed allergy treatment have been published in the Journal of Allergy and Clinical Immunology. The trial showed that the treatment was safe and effective in

Allergy Therapeutics Revenues Up 16%, Appoints New R&D Director

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Allergy Therapeutics boosts sales, gains market share

Allergy vaccine developer Allergy Therapeutics reported higher sales and revenue since July and said it was gaining share in all its main markets. The group said net revenues rose 16% in the first four months of this financial year against the same period last year while gross sales at constant cur

Allergy Therapeutics Hit By Challenging Conditions As Profit Declines

Monday broker round-up

AEC Education: WH Ireland places both its target price (prev.: 11p) and its recommendation under review. Aggreko: Citi reduces target price from 2100p to 2000p leaving its buy recommendation unaltered. Allergy Therapeutics: Panmure Gordon lowers target price from 18p to 16p, while keeping its buy

Allergy Therapeutics ends contract with Lincoln Medical

Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK. The pharmaceutical company said Lincoln Medical undertook a voluntary recall of all unexpired units of Apapen, an adrenali

Chamberlin Chairman invests 75k

Castings and engineering group Chamberlin announced on Monday that its Chairman has topped up his stake in the company twice over the couple of weeks. Keith Butler-Wheelhouse acquired a total of 44,500 Chamberlin ordinary shares through his family trust, BW Family Limited (BWFL), representing 0.56%

Shanks Chairman buys shares as profits fall

The Chairman of Shanks Group, the FTSE 250 waste management firm, has bought 60,000 shares in the firm following the company's announcement that half year profits fell by 29 per cent. Chairman Adrian Auer purchased the shares at 82.93p each for a total of £49,758. On Thursday the company revealed

Small caps round-up: Allergy, XCAP, Totally...

Allergy Therapeutics, a specialist pharmaceutical company focused on allergy vaccination, has welcomed the Food and Drugs Association's decision to lift the clinical hold on the company's grass pollen allergy vaccine clinical development programme, with immediate effect. Allergy has gained approval

Allergy gets FDA lift

Shareholders in allergy vaccine developer Allergy Therapeutics were making hay Tuesday after the US Food and Drug Administration (FDA) signalled the imminent lifting of the clinical hold on three of the company's products. The FDA said the clinical hold on the Investigational New Drug applications

London close: Flat day for FTSE 100

A second attempt to spring into life evaporated ahead of the close on Monday and the top share index finished just a few points higher. Worries that Japanese carmakers may have to suspend production at their plants in China following the earthquake disruption have sent copper prices lower. As a res

London afternoon: Shares mark time

Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t